TriangleLurbinectedin (NCT06228066)
Lurbinectedin trial for Small Cell Carcinoma of the Bladder (NCT06228066). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for people aged 18–120 with metastatic bladder small-cell cancer or other eligible urinary-tract high-grade neuroendocrine cancers, excluding prostate tumors. Prior platinum/etoposide treatment, ineligibility or refusal is required.
The idea: use lurbinectedin to disrupt cancer-driving gene transcription. Patients previously given checkpoint immunotherapy, or unable to receive it, get lurbinectedin alone. Eligible patients without prior checkpoint treatment also receive avelumab, which blocks PD-L1. Infusions repeat every three weeks. Researchers assess tumor response.
This phase 2 study plans 45 patients. Andrea Apolo leads at NIH in Bethesda, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.